CN109069466B - 5-ht6受体拮抗剂用于治疗阿尔茨海默病伴情感淡漠共病 - Google Patents

5-ht6受体拮抗剂用于治疗阿尔茨海默病伴情感淡漠共病 Download PDF

Info

Publication number
CN109069466B
CN109069466B CN201780028711.1A CN201780028711A CN109069466B CN 109069466 B CN109069466 B CN 109069466B CN 201780028711 A CN201780028711 A CN 201780028711A CN 109069466 B CN109069466 B CN 109069466B
Authority
CN
China
Prior art keywords
pharmaceutically acceptable
apathy
disease
alzheimer
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201780028711.1A
Other languages
English (en)
Chinese (zh)
Other versions
CN109069466A (zh
Inventor
K·T·奥德格伦
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
H Lundbeck AS
Original Assignee
H Lundbeck AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by H Lundbeck AS filed Critical H Lundbeck AS
Publication of CN109069466A publication Critical patent/CN109069466A/zh
Application granted granted Critical
Publication of CN109069466B publication Critical patent/CN109069466B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN201780028711.1A 2016-05-11 2017-05-09 5-ht6受体拮抗剂用于治疗阿尔茨海默病伴情感淡漠共病 Active CN109069466B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA201600286 2016-05-11
DKPA201600286 2016-05-11
PCT/EP2017/060979 WO2017194496A1 (en) 2016-05-11 2017-05-09 5ht6 receptor antagonists for use in the treatment of alzheimer's disease with apathy as comorbidity

Publications (2)

Publication Number Publication Date
CN109069466A CN109069466A (zh) 2018-12-21
CN109069466B true CN109069466B (zh) 2021-06-15

Family

ID=58707519

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780028711.1A Active CN109069466B (zh) 2016-05-11 2017-05-09 5-ht6受体拮抗剂用于治疗阿尔茨海默病伴情感淡漠共病

Country Status (7)

Country Link
US (1) US10864191B2 (https=)
EP (1) EP3454848B1 (https=)
JP (2) JP6961622B2 (https=)
CN (1) CN109069466B (https=)
BR (1) BR112018000568A2 (https=)
ES (1) ES2826386T3 (https=)
WO (1) WO2017194496A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10864191B2 (en) * 2016-05-11 2020-12-15 H. Lundbeck A/S 5-HT6 receptor antagonists for use in the treatment of Alzheimer's disease with apathy as comorbidity
BR112019001145A2 (pt) * 2017-05-24 2019-04-30 H. Lundbeck A/S combinação de um antagonista do receptor 5-ht6 e de um inibidor de acetilcolinesterase para uso no tratamento da doença de alzheimer em uma subpopulação de pacientes portadores de alelos de apoe4
CA3104811C (en) * 2017-06-30 2024-05-28 Chase Therapeutics Corporation Composition comprising pramipexole and nk1-antagonists for treating depression
JP2023510082A (ja) 2019-12-02 2023-03-13 スヴェン・ライフ・サイエンシーズ・リミテッド 認知症患者における行動・心理症状を治療するための方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009093206A2 (ru) * 2008-01-24 2009-07-30 Alla Chem, Llc 3-CУЛЬФOHИЛ-ПИPAЗOЛO[1,5-a]ПИPИMИДИHЫ - АНТАГОНИСТЫ СЕРОТОНИНОВЫХ 5-HT6РЕЦЕПТОРОВ, СПОСОБЫ ИХ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЯ
CN104619344A (zh) * 2012-09-09 2015-05-13 H.隆德贝克有限公司 治疗阿尔茨海默病的方法及其药物组合物

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2006641A (en) * 1932-09-26 1935-07-02 Charles E Johnson Hydraulic tappet
DK1859798T3 (en) 2001-03-29 2016-03-21 Lilly Co Eli N- (2-arylethyl) -BENZYLAMINER as antagonists of 5-HT6 receptor
PE20071143A1 (es) * 2006-01-13 2008-01-20 Wyeth Corp Composicion farmaceutica que comprende un inhibidor de acetilcolinesterasa y un antagonista 5-hidroxitriptamina-6
AR061637A1 (es) 2006-06-26 2008-09-10 Epix Delaware Inc Composiciones y metodos de tratamiento de trastornos del snc
EP2508177A1 (en) 2007-12-12 2012-10-10 Glaxo Group Limited Combinations comprising 3-phenylsulfonyl-8-piperazinyl-1yl-quinoline
US8629154B2 (en) 2008-01-24 2014-01-14 Andrey Alexandrovich Ivashchenko Substituted cycloalcano[e and d] pyrazolo [1,5-a]pyrimidines/antagonists of serotonin 5-HT6 receptors and methods for production and the use thereof
KR20100119776A (ko) 2008-01-24 2010-11-10 알라 캠, 엘엘씨 2-알킬아미노-3-아릴설포닐-사이클로알카노[ｅ 또는 ｄ]피라졸로[1,5-Ａ]피리미딘/세로토닌 5-ＨＴ6 수용체의 길항제, 이의 제조방법 및 이의 용도
US8309559B2 (en) 2008-01-24 2012-11-13 Nikolay Filippovich Savchuk (EN) substituted 2-amino-3-sulfonyl-pyrazolo[1,5-A] pyrimidines/antagonists of serotonin 5-HT6 receptors, methods for the production and the use thereof
US10864191B2 (en) 2016-05-11 2020-12-15 H. Lundbeck A/S 5-HT6 receptor antagonists for use in the treatment of Alzheimer's disease with apathy as comorbidity

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009093206A2 (ru) * 2008-01-24 2009-07-30 Alla Chem, Llc 3-CУЛЬФOHИЛ-ПИPAЗOЛO[1,5-a]ПИPИMИДИHЫ - АНТАГОНИСТЫ СЕРОТОНИНОВЫХ 5-HT6РЕЦЕПТОРОВ, СПОСОБЫ ИХ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЯ
CN104619344A (zh) * 2012-09-09 2015-05-13 H.隆德贝克有限公司 治疗阿尔茨海默病的方法及其药物组合物

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
A prospective longitudinal study of apathy in Alzheimer’s disease;S E Starkstein;《J Neurol Neurosurg Psychiatry》;20051216;第77卷(第1期);第8-11页 *
Identification of a novel series of 3-piperidinyl-5-sulfonylindazoles as potent 5-HT6 ligands;Kevin G. Liu;《Bioorganic & Medicinal Chemistry Letters》;20090503;第3214-3216页 *
Kevin G. Liu.Identification of a novel series of 3-piperidinyl-5-sulfonylindazoles as potent 5-HT6 ligands.《Bioorganic & Medicinal Chemistry Letters》.2009,第3214-3216页. *
Safety and effi cacy of idalopirdine, a 5-HT6 receptor antagonist, in patients with moderate Alzheimer’s disease (LADDER): a randomised, double-blind, placebo-controlled phase 2 trial;David Wilkinson;《Lancet Neurol》;20141006;第13卷(第11期);第1092-1099页 *
The 5-HT6 receptor antagonist idalopirdine potentiates the effects of acetylcholinesterase inhibition on neuronal network oscillations and extracellular acetylcholine levels in the rat dorsal hippocampus;Kjartan F. Herrik;《Neuro pharmacology》;20160331(第107期);第351-363页 *

Also Published As

Publication number Publication date
EP3454848B1 (en) 2020-09-09
US10864191B2 (en) 2020-12-15
JP6961622B2 (ja) 2021-11-05
US20170326107A1 (en) 2017-11-16
JP2019518736A (ja) 2019-07-04
WO2017194496A1 (en) 2017-11-16
ES2826386T3 (es) 2021-05-18
JP2022009121A (ja) 2022-01-14
EP3454848A1 (en) 2019-03-20
BR112018000568A2 (pt) 2018-09-11
CN109069466A (zh) 2018-12-21
JP7217789B2 (ja) 2023-02-03

Similar Documents

Publication Publication Date Title
AU2019203448B2 (en) Fenfluramine for use in the treatment of dravet syndrome
JP7217789B2 (ja) 併存疾患としてアパシーを伴うアルツハイマー病の治療における使用のための５－ｈｔ６受容体アンタゴニスト
US20120010242A1 (en) Low dose pipamperone in treating mood disorders
US11464759B2 (en) 5-HT6 receptor antagonists for use in the treatment of alzheimer's disease in patient subpopulation carrying APOE4 alleles
HK40001557A (en) 5ht6 receptor antagonists for use in the treatment of alzheimer's disease with apathy as comorbidity
HK40001557B (en) 5ht6 receptor antagonists for use in the treatment of alzheimer's disease with apathy as comorbidity
RU2776366C2 (ru) Комбинация антагониста 5-ht6-рецептора и ингибитора ацетилхолинэстеразы для применения при лечении болезни альцгеймера у субпопуляции пациентов, которые являются носителями аллелей apoe4
CA3063968C (en) Combination of a 5-ht6 receptor antagonist and an acetylcholinesterase inhibitor for use in the treatment of alzheimer's disease in a patient subpopulation carrying apoe4 alleles
HK40027190B (en) Combination of a 5-ht6 receptor antagonist and an acetylcholinesterase inhibitor for use in the treatment of alzheimer's disease in a patient subpopulation carrying apoe4 alleles
HK40027190A (en) Combination of a 5-ht6 receptor antagonist and an acetylcholinesterase inhibitor for use in the treatment of alzheimer's disease in a patient subpopulation carrying apoe4 alleles
CN1466587A (zh) 含有2-芳基-8-氧代二氢嘌呤衍生物作为活性成分的痴呆症治疗剂
KR20220108123A (ko) 치매 환자의 행동 및 심리적 증상 치료
HK1256346A1 (en) Fenfluramine for use in the treatment of dravet syndrome
HK1256346B (en) Fenfluramine for use in the treatment of dravet syndrome
KR20060130689A (ko) 인지 기능의 감퇴를 억제하기 위한 혼합 약제 조성물
WO2013168315A1 (ja) 認知症及び行動心理学的症候の治療又は予防剤

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant